{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:27:23Z","timestamp":1793046443555,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T00:00:00Z","timestamp":1607126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T00:00:00Z","timestamp":1607126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A2A1A05078480"],"award-info":[{"award-number":["2018R1A2A1A05078480"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2015R1A2A1A10054579"],"award-info":[{"award-number":["NRF-2015R1A2A1A10054579"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1C1B5017389"],"award-info":[{"award-number":["2017R1C1B5017389"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["1720160"],"award-info":[{"award-number":["1720160"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"name":"This study was supported by a grant (HCRI20018) Chonnam National University Hwasun Hospital Institute for Biomedical Science."},{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["PGS-D"],"award-info":[{"award-number":["PGS-D"]}],"id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41409-020-01165-x","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T11:02:21Z","timestamp":1607166141000},"page":"1159-1170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0782-2261","authenticated-orcid":false,"given":"Jae-Sook","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TaeHyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Yeon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Yeon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Young","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Hwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungHyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3756-796X","authenticated-orcid":false,"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6454-8030","authenticated-orcid":false,"given":"Hui Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8804-2616","authenticated-orcid":false,"given":"Yu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Yoon","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-3117","authenticated-orcid":false,"given":"Igor","family":"Novitzky-Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7303-6472","authenticated-orcid":false,"given":"Zhaolei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-1090","authenticated-orcid":false,"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"1165_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood."},{"key":"1165_CR2","doi-asserted-by":"publisher","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","volume":"15","author":"MR O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:926\u201357.","journal-title":"J Natl Compr Canc Netw"},{"key":"1165_CR3","first-page":"1441","volume":"69","author":"H Preisler","year":"1987","unstructured":"Preisler H, Davis RB, Kirshner J, Dupre E, Richards F 3rd, Hoagland HC, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood. 1987;69:1441\u20139.","journal-title":"Blood."},{"key":"1165_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1182\/blood.V79.2.313.313","volume":"79","author":"PH Wiernik","year":"1992","unstructured":"Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313\u20139.","journal-title":"Blood."},{"key":"1165_CR5","doi-asserted-by":"publisher","first-page":"e0132620","DOI":"10.1371\/journal.pone.0132620","volume":"10","author":"D Li","year":"2015","unstructured":"Li D, Wang L, Zhu H, Dou L, Liu D, Fu L, et al. Efficacy of allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia adult patients in first complete remission: a meta-analysis of prospective studies. PLoS ONE. 2015;10:e0132620.","journal-title":"PLoS ONE"},{"key":"1165_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","volume":"32","author":"M Stelljes","year":"2014","unstructured":"Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol. 2014;32:288\u201396.","journal-title":"J Clin Oncol"},{"key":"1165_CR7","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.18632\/oncotarget.23575","volume":"9","author":"JS Ahn","year":"2018","unstructured":"Ahn JS, Kim HJ, Kim YK, Lee SS, Ahn SY, Jung SH, et al. Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. Oncotarget. 2018;9:4961\u20138.","journal-title":"Oncotarget."},{"key":"1165_CR8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"N Cancer Genome Atlas Research","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl J Med. 2013;368:2059\u201374.","journal-title":"N. Engl J Med"},{"key":"1165_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/ejh.12336","volume":"93","author":"M Bastos-Oreiro","year":"2014","unstructured":"Bastos-Oreiro M, Perez-Corral A, Martinez-Laperche C, Bento L, Pascual C, Kwon M, et al. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Eur J Haematol. 2014;93:239\u201346.","journal-title":"Eur J Haematol"},{"key":"1165_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment oF Minimal Residual Disease in Standard-risk AML. N. Engl J Med. 2016;374:422\u201333.","journal-title":"N. Engl J Med"},{"key":"1165_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189\u201399.","journal-title":"N Engl J Med"},{"key":"1165_CR12","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","volume":"121","author":"E Jourdan","year":"2013","unstructured":"Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121:2213\u201323.","journal-title":"Blood."},{"key":"1165_CR13","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","volume":"36","author":"K Morita","year":"2018","unstructured":"Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, et al. Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol. 2018;36:1788\u201397.","journal-title":"J Clin Oncol"},{"key":"1165_CR14","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","volume":"114","author":"S Schnittger","year":"2009","unstructured":"Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114:2220\u201331.","journal-title":"Blood."},{"key":"1165_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","volume":"122","author":"N Shayegi","year":"2013","unstructured":"Shayegi N, Kramer M, Bornhauser M, Schaich M, Schetelig J, Platzbecker U, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. 2013;122:83\u201392.","journal-title":"Blood."},{"key":"1165_CR16","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","volume":"31","author":"M Terwijn","year":"2013","unstructured":"Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol. 2013;31:3889\u201397.","journal-title":"J Clin Oncol"},{"key":"1165_CR17","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, et al. Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016;30:1456\u201364.","journal-title":"Leukemia."},{"key":"1165_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","volume":"35","author":"M Balsat","year":"2017","unstructured":"Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. J Clin Oncol. 2017;35:185\u201393.","journal-title":"J Clin Oncol"},{"key":"1165_CR19","doi-asserted-by":"crossref","unstructured":"Forghieri F, Comoli P, Marasca R, Potenza L, Luppi M. Minimal\/measurable residual disease monitoring in NPM1-mutated acute myeloid leukemia: a clinical viewpoint and perspectives. Int J Mol Sci. 20186;19:3492.","DOI":"10.3390\/ijms19113492"},{"key":"1165_CR20","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","volume":"29","author":"J Kronke","year":"2011","unstructured":"Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI, et al. J Clin Oncol. 2011;29:2709\u201316.","journal-title":"J Clin Oncol"},{"key":"1165_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/blood-2009-04-212530","volume":"115","author":"HB Ommen","year":"2010","unstructured":"Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, Ostergaard M, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115:198\u2013205.","journal-title":"Blood."},{"key":"1165_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","volume":"122","author":"J Kronke","year":"2013","unstructured":"Kronke J, Bullinger L, Teleanu V, Tschurtz F, Gaidzik VI, Kuhn MW, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122:100\u20138.","journal-title":"Blood."},{"key":"1165_CR23","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.3324\/haematol.2018.188433","volume":"103","author":"C Martinez-Losada","year":"2018","unstructured":"Martinez-Losada C, Serrano-Lopez J, Serrano-Lopez J, Noguera NI, Garza E, Piredda L, et al. Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. Haematologica. 2018;103:e400\u20133.","journal-title":"Haematologica."},{"key":"1165_CR24","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"1165_CR25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jama.2015.9643","volume":"314","author":"JM Klco","year":"2015","unstructured":"Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314:811\u201322.","journal-title":"JAMA."},{"key":"1165_CR26","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","volume":"32","author":"M Rothenberg-Thurley","year":"2018","unstructured":"Rothenberg-Thurley M, Amler S, Goerlich D, Kohnke T, Konstandin NP, Schneider S, et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018;32:1598\u2013608.","journal-title":"Leukemia."},{"key":"1165_CR27","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","volume":"132","author":"T Kim","year":"2018","unstructured":"Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, et al. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Blood. 2018;132:1604\u201313.","journal-title":"Blood."},{"key":"1165_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/leu.2015.264","volume":"30","author":"T Kim","year":"2016","unstructured":"Kim T, Yoshida K, Kim YK, Tyndel MS, Park HJ, Choi SH, et al. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression. Leukemia. 2016;30:295\u2013302.","journal-title":"Leukemia."},{"key":"1165_CR29","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616\u201327.","journal-title":"Blood."},{"key":"1165_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1165_CR31","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3324\/haematol.2013.100784","volume":"99","author":"J Delgado","year":"2014","unstructured":"Delgado J, Pereira A, Villamor N, Lopez-Guillermo A, Rozman C. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014;99:1410\u201320.","journal-title":"Haematologica."},{"key":"1165_CR32","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","volume":"20","author":"P Gorello","year":"2006","unstructured":"Gorello P, Cazzaniga G, Alberti F, Dell\u2019Oro MG, Gottardi E, Specchia G, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20:1103\u20138.","journal-title":"Leukemia."},{"key":"1165_CR33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","volume":"17","author":"MS Tallman","year":"2019","unstructured":"Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17:721\u201349.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1165_CR34","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703\u201313.","journal-title":"Blood."},{"key":"1165_CR35","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","volume":"36","author":"SD Freeman","year":"2018","unstructured":"Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, et al. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018;36:1486\u201397.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01165-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01165-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01165-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:17Z","timestamp":1684617437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01165-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01165-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,5]]},"assertion":[{"value":"12 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}